C106

C106 is a small molecule drug that functions as an **angiotensin II type 2 receptor agonist** (AT2R agonist). It was developed as a novel, orally available agent with **target engagement and anti-fibrotic effects** in human fibrotic lung and kidney tissue at clinically relevant concentrations. The drug demonstrated favorable preclinical activity but was discontinued following its initial phase 1 clinical trial because of dose-dependent increases in blood pressure, which were thought to be due to partial activity at the angiotensin II type 1 receptor (AT1R). The main developer was Vicore Pharma, initially developed by HaLaCore Pharma. Its primary clinical indications were pulmonary hypertension and idiopathic pulmonary fibrosis.[1][2][4]

Other names

C106C-106C 106ATRAG-C106ATRAG-C-106ATRAG-C 106